Parkinson

Encouraging trial results from Anavex


The clinical trial was a double blind study, meaning that none of the participants involved knew which treatment (placebo or blarcamesine) each was receiving. The participants were treated for 14 weeks, during which they were clinically assessed to determine if the treatment was having an effect.

After analysing the results, the investigators reported that blarcamesine treatment led to a significant improvement in cognitive test scores, but also an 11 point increase in motor scores in the treated group (as opposed to a 3.5 point decline in the placebo group). In the press release, the company has indicated that with these positive results they are seeking regulatory guidance on how to proceed with their clinical development of blarcamesine.



Source Link


DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

odiseases.com

diseases, diagnosis and treatment methods, drugs and their side effects on this site. online diseases, diagnosis and treatment methods

Related Articles

Back to top button
%d bloggers like this: